Galectin Therapeutics (GALT) Short-Term Debt issuances (2022 - 2026)

Galectin Therapeutics has reported Short-Term Debt issuances for 5 years, with the latest figure at $257000.0 in Q1 2026.

• For the quarter ending Q1 2026, Short-Term Debt issuances changed N/A year-over-year to $257000.0; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (down 48.72% YoY), and the FY2025 full-year result was $10.0 million, down 66.67% from the prior year.
• Short-Term Debt issuances for Q1 2026 stood at $257000.0, down from $10.0 million in the prior quarter.
• The five-year high for Short-Term Debt issuances was $10.0 million in Q4 2022, with the low at $257000.0 in Q1 2026.
• Average Short-Term Debt issuances over 5 years is $8.5 million, with a median of $10.0 million recorded in 2022.
• Year-over-year, Short-Term Debt issuances changed 0.0% in 2023 and sank 50.0% in 2025.
• Tracing GALT's Short-Term Debt issuances over 5 years: stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then changed by 0.0% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then plunged by 97.43% to $257000.0 in 2026.
• The last three Short-Term Debt issuances figures came in at $257000.0 (Q1 2026), $10.0 million (Q4 2025), and $5.0 million (Q2 2025), per Business Quant data.

Peer Comparison